Logo image
Se connecter
Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus
Article de revue   Avec comité de lecture

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, …
Clinical infectious diseases, Vol.69(1), pp.144-146
18/06/2019
PMID: 30924492

Résumé

Immunology Infectious Diseases Life Sciences & Biomedicine Microbiology Science & Technology
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth.

Indicateurs

1 Consultations de la notice

Détails

Logo image